Sutro Biopharma (STRO) Long-Term Investments (2019 - 2022)

Sutro Biopharma has disclosed Long-Term Investments across 4 years of filings, most recently posting $20.7 million for Q1 2022.

• Long-Term Investments for Q1 2022 came in at $20.7 million, down 72.25% year-over-year; the trailing twelve-month figure through Mar 2022 was $20.7 million (down 72.25% YoY), and the FY2021 annual result was $68.8 million, changed N/A from the prior year.
• Long-Term Investments came in at $20.7 million for Q1 2022 at Sutro Biopharma, down from $68.8 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $74.6 million in Q1 2021 to a low of $5.6 million in Q2 2020.
• The 4-year median for Long-Term Investments is $20.7 million (2022), against an average of $34.3 million.
• Across the five-year window, Long-Term Investments surged 971.43% in 2021 and tumbled 72.25% in 2022, its largest moves.
• Sutro Biopharma's Long-Term Investments stood at $15.6 million in 2019, then tumbled by 64.12% to $5.6 million in 2020, then surged by 1128.57% to $68.8 million in 2021, then slumped by 69.91% to $20.7 million in 2022.
• The last three Long-Term Investments figures came in at $20.7 million (Q1 2022), $68.8 million (Q4 2021), and $64.3 million (Q3 2021), per Business Quant data.